Bio-Techne (TECH) Non-Current Debt (2014 - 2026)
Bio-Techne (TECH) recorded quarterly Non-Current Debt of $200.0 million in Q1 2026, down 23.08% quarter-over-quarter from $260.0 million in Q4 2025, and down 39.39% on a YoY basis from $330.0 million in Q1 2025.
Bio-Techne (TECH) Non-Current Debt (2014 - 2026) Analysis & Trends
Bio-Techne's Non-Current Debt history runs 13 years deep, the most recent figure standing at $200.0 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 39.39% year-over-year to $200.0 million; the TTM figure through Mar 2026 stood at $200.0 million (down 39.39% YoY), while the FY2025 annual figure was $346.0 million, up 8.46% from the prior year.
- Non-Current Debt was $200.0 million for Q1 2026 at Bio-Techne, down from $260.0 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $447.0 million in Q4 2023 to a low of $200.0 million in Q4 2022.
- Historically, Non-Current Debt has averaged $312.1 million across 5 years, with a median of $300.0 million in 2024.
- The sharpest annual moves came in 2023 and 2026: Non-Current Debt surged 123.5% in 2023, then sank 39.39% in 2026.
- A 5-year view of Non-Current Debt shows it stood at $200.0 million in 2022, then surged by 123.5% to $447.0 million in 2023, then tumbled by 32.89% to $300.0 million in 2024, then fell by 13.33% to $260.0 million in 2025, then decreased by 23.08% to $200.0 million in 2026.
- The last three Non-Current Debt figures came in at $200.0 million (Q1 2026), $260.0 million (Q4 2025), and $300.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Bio-Techne | 9.04 Bn | 8.83 Bn | 208.29 Mn | 200.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200.00 Mn |
| Mar 31, 2026 | 200.00 Mn |
| Dec 31, 2025 | 260.00 Mn |
| Dec 31, 2025 | 260.00 Mn |
| Sep 30, 2025 | 300.00 Mn |
| Sep 30, 2025 | 300.00 Mn |
| Jun 30, 2025 | 346.00 Mn |
| Jun 30, 2025 | 346.00 Mn |
| Mar 31, 2025 | 330.00 Mn |
| Mar 31, 2025 | 330.00 Mn |
| Dec 31, 2024 | 300.00 Mn |
| Dec 31, 2024 | 300.00 Mn |
| Sep 30, 2024 | 300.00 Mn |
| Sep 30, 2024 | 300.00 Mn |
| Jun 30, 2024 | 319.00 Mn |
| Jun 30, 2024 | 319.00 Mn |
| Mar 31, 2024 | 389.00 Mn |
| Mar 31, 2024 | 389.00 Mn |
| Dec 31, 2023 | 447.00 Mn |
| Dec 31, 2023 | 447.00 Mn |